文献速递妇科

晚期和复发性子宫内膜癌的基因组特征:KRAS与TP53共突变作为不良预后和治疗失败的生物标志物

Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure.
PubMed 文献 · Gynecol Oncol · 2026-10-15

该研究对67例子宫内膜癌患者(41例早期,26例晚期/复发)肿瘤样本进行全外显子测序的体细胞突变分析,比较早期与晚期/复发性EC的突变频率并进行拷贝数变异分析。结果显示KRAS-TP53共突变与晚期EC最差生存结局相关(p=0.011),且所有共突变病例均化疗耐药,在拷贝数低和微卫星高度不稳定肿瘤中该关联亦显著(p=0.003)。

要点

  • KRAS-TP53共突变是晚期EC不良预后和化疗耐药的潜在分子标志物。
  • 晚期EC中TP53和KRAS突变频率更高,缺失也更常见(42.3% vs 17.1%)。
  • 在CNL和MSI-H肿瘤中,KRAS-TP53共突变与不良生存结局强相关(p=0.003)。

核心结论

  • KRAS-TP53共突变是晚期子宫内膜癌不良预后和化疗耐药的潜在分子生物标志物。

研究设计与样本

  • 对67例EC患者(41例早期,26例晚期/复发)肿瘤样本进行基于全外显子测序的体细胞突变谱分析,并分析拷贝数变异。

主要发现

  • 晚期/复发EC中TP53和KRAS突变频率趋于更高,缺失更常见(42.3% vs 17.1%)。
  • 26例晚期EC中16例复发,复发者TP53突变率显著更高(56.3% vs 10%),PTEN突变率更低(25% vs 80%)。
  • 晚期EC中KRAS单突变仅显示OS缩短趋势(p=0.179),KRAS-TP53共突变生存结局最差(p=0.011)。
  • KRAS-TP53共突变与化疗耐药相关:所有共突变病例均化疗耐药,而无任一突变者化疗敏感。
  • 在CNL和MSI-H肿瘤中(n=46),KRAS-TP53共突变与不良生存结局强相关(p=0.003)。

临床怎么用

  • 对晚期EC进行KRAS和TP53共突变检测可能有助于识别预后差和化疗耐药的患者。
  • KRAS-TP53共突变或可细化TCGA分类,尤其对CNL和MSI-H亚组。
  • 共突变状态可支持探索KRAS靶向治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The survival outcomes of advanced or recurrent endometrial cancer (EC) have not improved markedly despite the expanding therapeutic options. We performed molecular characterization of EC to identify therapeutic targets and prognostic biomarkers. METHODS: Whole-exome sequencing (WES)-based somatic mutation profiling was performed in tumor samples obtained from 67 EC patients (41 early-stage and 26 advanced/recurrent cases). The frequencies of somatic mutations were compared between early and advanced/recurrent EC. Copy number variation analysis was also performed. Survival outcomes and recurrences according to mutational status were analyzed. RESULTS: TP53 and KRAS mutations tended to be more frequent in advanced/recurrent disease than early-stage EC. Deletions were also more common in advanced EC (42.3% vs. 17.1%). Among the advanced EC patients (n=26), 16 patients recurred. Recurrent cases had significantly higher TP53 mutation rates (56.3% versus 10%) and lower PTEN mutation rates (25% versus 80%) than non-recurrent cases. KRAS and CTNNB1 mutations also tended to be enriched. Although KRAS mutation alone only showed a trend of shorter OS (p=0.179) in advanced EC, KRAS-TP53 co-mutation exhibited the worst survival outcomes (p=0.011). KRAS-TP53 co-mutation was associated with chemoresistance: all the co-mutated cases were chemoresistant, whereas patients without either mutation were chemosensitive. Among copy-number low (CNL) and microsatellite instability-high (MSI-H) tumors (n=46), KRAS-TP53 co-mutation was strongly associated with adverse survival outcomes (p=0.003). CONCLUSIONS: KRAS-TP53 co-mutation represents a potential molecular biomarker of poor prognosis and chemoresistance in advanced EC. It may enable refinement of TCGA classification, especially for CNL and MSI-H subgroups, and support investigation of KRAS-targeted therapeutic strategies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee S, So KA, Kim S, et al. Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure. Gynecol Oncol. 2026. PMID: 42880205. doi:10.1016/j.ygyno.2026.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。